Delcath Q3 revenue $11.2M (+44% QoQ); HEPZATO adoption grows; debt-free after warrant exercise

DELCATH SYSTEMS, INC.

2024-Q3 EPS reported -$0.84 revenue$22,105,000

Q3 total revenue $11.2M (vs $0.4M prior year); HEPZATO $10.0M, CHEMOSAT $1.2M.
Activated 12 HEPZATO treatment centers in U.S.; additional centers in training pipeline.
Ended Q3 with $14.0M cash; quarterly cash burn $3.6M.
Post-Q3: paid $2.8M final Rosalind note; ~$25M from Tranche B warrant exercise; no debt.
Advancing HEPZATO programs for liver-dominant colorectal and breast cancers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.